A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how to design a vaccine ...

I am writing to voice concerns over the findings of the phase 3 trial of the R21/Matrix-M malaria vaccine by Mehreen Datoo and colleagues.1 The study indicates that the vaccine's efficacy appears to ...

We thank the authors for their interest in our paper, and their queries. In response to Yue Li and Guangsen Liu, given the current situation of malaria deaths and cases increasing in recent years,1 it ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The U.S. Department of Health and Human Services (HHS) has announced $590 million in funding to Moderna to expedite the ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Moderna's been anything but a high-flying growth stock in this investor's portfolio. So is it high time he gave up on this one? The post Moderna’s meant to be a red-hot growth stock. What on earth’s ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...